SMMT Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -- compared to Summit Therapeutics's net margin of 16.61%. Summit Therapeutics's return on equity of -- beat Gilead Sciences's return on equity of 0.64%.

Summit Therapeutics has a consensus price target of $32.85, signalling upside risk potential of 80.75%. On the other hand Gilead Sciences has an analysts' consensus of $99.96 which suggests that it could grow by 11.14%. Given that Summit Therapeutics has higher upside potential than Gilead Sciences, analysts believe Summit Therapeutics is more attractive than Gilead Sciences.

Summit Therapeutics has a beta of -0.868, which suggesting that the stock is 186.829% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.12%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.43% to investors and pays a quarterly dividend of $0.77 per share. Summit Therapeutics pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Summit Therapeutics quarterly revenues are --, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Summit Therapeutics's net income of -$56.3M is lower than Gilead Sciences's net income of $1.3B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 999.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 13,487.86x versus 3.98x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Summit Therapeutics's net margin of 18.95%. Summit Therapeutics's return on equity of -- beat Merck &'s return on equity of 29.26%.

Summit Therapeutics has a consensus price target of $32.85, signalling upside risk potential of 80.75%. On the other hand Merck & has an analysts' consensus of $127.05 which suggests that it could grow by 25.81%. Given that Summit Therapeutics has higher upside potential than Merck &, analysts believe Summit Therapeutics is more attractive than Merck &.

Summit Therapeutics has a beta of -0.868, which suggesting that the stock is 186.829% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.09% to investors and pays a quarterly dividend of $0.81 per share. Summit Therapeutics pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Summit Therapeutics's net income of -$56.3M is lower than Merck &'s net income of $3.2B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 21.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 13,487.86x versus 4.06x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Summit Therapeutics's net margin of 0.7%. Summit Therapeutics's return on equity of -- beat Moderna's return on equity of -17.44%.

Summit Therapeutics has a consensus price target of $32.85, signalling upside risk potential of 80.75%. On the other hand Moderna has an analysts' consensus of $73.19 which suggests that it could grow by 108.21%. Given that Moderna has higher upside potential than Summit Therapeutics, analysts believe Moderna is more attractive than Summit Therapeutics.

Summit Therapeutics has a beta of -0.868, which suggesting that the stock is 186.829% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Moderna quarterly revenues of $1.9B. Summit Therapeutics's net income of -$56.3M is lower than Moderna's net income of $13M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 13,487.86x versus 2.69x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Summit Therapeutics's net margin of --. Summit Therapeutics's return on equity of -- beat Viking Therapeutics's return on equity of --.

Summit Therapeutics has a consensus price target of $32.85, signalling upside risk potential of 80.75%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 182.92%. Given that Viking Therapeutics has higher upside potential than Summit Therapeutics, analysts believe Viking Therapeutics is more attractive than Summit Therapeutics.

Summit Therapeutics has a beta of -0.868, which suggesting that the stock is 186.829% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Summit Therapeutics's net income of -$56.3M is lower than Viking Therapeutics's net income of -$24.9M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 13,487.86x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.